Flagship Pioneering-backed startup Lila Sciences secured $235 million in Series A funding to develop 'scientific superintelligence' by integrating artificial intelligence into laboratory research processes. This financing will support the company's ambition to revolutionize the drug discovery workflow through autonomous AI-powered platforms, potentially accelerating therapeutic development and precision medicine advancements.